![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
OSE Immunotherapeutics | EU:OSE | Euronext | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.70 | 10.13% | 7.61 | 7.45 | 7.65 | 7.67 | 6.84 | 6.90 | 464,450 | 16:40:00 |
On February 28, 2024, at 6:00 p.m. CET / 12:00 a.m. ET.
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), will host a live webcast on February 28, 2024, at 6:00 p.m. CET to discuss the global collaboration and license agreement with AbbVie and outline the Company’s strategic focus moving forward.
The live webcast will be available at the following link:
WEBCAST
Link: https://channel.royalcast.com/landingpage/oseimmunotherapeutics-en/20240228_1/
A replay of the webcast following the event will be available on the Company’s website: https://ose-immuno.com/en/
ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I). The Company’s current well-balanced first-in-class clinical pipeline includes:
OSE Immunotherapeutics expects to generate further significant value from its three proprietary drug discovery platforms, which are central to its ambitious goal to deliver next-generation first-in-class immunotherapies:
Additional information about OSE Immunotherapeutics assets is available on the Company’s website: www.ose-immuno.com Click and follow us on Twitter and LinkedIn
Forward-looking statements This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics’ management in light of its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as “expect”, “anticipate”, “believe”, “target”, “plan”, or “estimate”, their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics’ shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on May 2, 2023, including the annual financial report for the fiscal year 2022, available on the OSE Immunotherapeutics’ website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227277635/en/
Sylvie Détry sylvie.detry@ose-immuno.com
Nicolas Poirier Chief Executive Officer nicolas.poirier@ose-immuno.com
French Media: FP2COM Florence Portejoie fportejoie@fp2com.fr +33 6 07 768 283
U.S. Media Contact RooneyPartners LLC Kate Barrette kbarrette@rooneypartners.com +1 212 223 0561
1 Year OSE Immunotherapeutics Chart |
1 Month OSE Immunotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions